The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management

References

• Diehl V, Sextro M, Franklin J, . Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776–783.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Jackson H, Parker F: Hodgkin's disease. I. General considerations. N Engl J Med 1944;230:1–8.
   Google Scholar
• Harris NL, Jaffe ES, Stein H, . Lymphoma classification proposal: clarification. Blood 1995;85:857–860.
   PubMed Web of Science ®Google Scholar
• Jackson C, Sirohi B, Cunningham D, . Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010;21:2061–2068.
   PubMed Web of Science ®Google Scholar
• Biasoli I, Stamatoullas A, Meignin V, . Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010;116:631–639.
   PubMed Web of Science ®Google Scholar
• Chen RC, Chin MS, Ng AK, . Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136–141.
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Brillant C, . Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434–439.
   PubMed Web of Science ®Google Scholar
• Crossley B, Heryet A, Gatter KC. Does nodular lymphocyte predominant Hodgkin's disease arise from progressively transformed germinal centres? A case report with an unusually prolonged history. Histopathology 1987;11:621–630.
   PubMed Web of Science ®Google Scholar
• Burns BF, Colby TV, Dorfman RF. Differential diagnostic features of nodular L & H Hodgkin's disease, including progressive transformation of germinal centers. Am J Surg Pathol 1984;8:253–261.
   PubMed Web of Science ®Google Scholar
• Hansmann ML, Fellbaum C, Hui PK, . Progressive transformation of germinal centers with and without association to Hodgkin's disease. Am J Clin Pathol 1990;93:219–226.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, . Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429–433.
   PubMed Web of Science ®Google Scholar
• Kahn ST, Flowers C, Lechowicz MJ, . Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:961–965.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, O'Doherty MJ, . 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543–553.
   PubMed Web of Science ®Google Scholar
• Ansquer C, Hervouet T, Devillers A, . 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica 2008;93:128–131.
   PubMed Web of Science ®Google Scholar
• Rehani B, Dowdy Y, Bharija A, . F18 fluorodeoxyglucose uptake in progressive transformation of germinal centres. Biomed Imaging Interv J 2008;4:e6.
   Google Scholar
• Feugier P, Labouyrie E, Djeridane M, . Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004;104:2675–2681.
   PubMed Web of Science ®Google Scholar
• Wirth A, Yuen K, Barton M, . Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005;104:1221–1229.
   PubMed Web of Science ®Google Scholar
• Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063–1083.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th. Lyon: IARC; 2008.
   Google Scholar
• Boudova L, Torlakovic E, Delabie J, . Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003;102:3753–3758.
   PubMed Web of Science ®Google Scholar
• Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989;135:351–357.
   PubMed Web of Science ®Google Scholar
• Falini B, Bigerna B, Pasqualucci L, . Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996;87:465–471.
   PubMed Web of Science ®Google Scholar
• Liso A, Capello D, Marafioti T, . Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006;108:1013–1020.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Stul M, De Wolf-Peeters C, . Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma. Haematologica 2004;89:965–972.
   PubMed Web of Science ®Google Scholar
• Fan Z, Natkunam Y, Bair E, . Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346–1356.
   PubMed Web of Science ®Google Scholar
• Prakash S, Fountaine T, Raffeld M, . IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 2006;30:585–592.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I, Hansmann ML, Franssila K, . European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889–1899.
   PubMed Web of Science ®Google Scholar
• Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 1991;2(Suppl. 2):77–82.
   PubMed Web of Science ®Google Scholar
• Dores GM, Metayer C, Curtis RE, . Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484–3494.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Douglas AJ, Hudson GV, . Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137–1143.
   PubMed Web of Science ®Google Scholar
• Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, . Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007;110:179–185.
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Terrier-Lacombe MJ, Oberlin O, . Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003;21:2948–2952.
   PubMed Web of Science ®Google Scholar
• Wilder RB, Schlembach PJ, Jones D, . European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002;94:1731–1738.
   PubMed Web of Science ®Google Scholar
• Schlembach PJ, Wilder RB, Jones D, . Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002;8:377–383.
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Eich HT, . Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005;16:1683–1687.
   PubMed Web of Science ®Google Scholar
• Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v168–v171.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: v2.2011 guideline on Hodgkin Lymphoma. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 05, 2011.
   Google Scholar
• Orlandi E, Lazzarino M, Brusamolino E, . Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997;26:359–368.
   PubMed Web of Science ®Google Scholar
• Karayalcin G, Behm FG, Gieser PW, . Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment—the Pediatric Oncology Group experience. Med Pediatr Oncol 1997;29:519–525.
   PubMedGoogle Scholar
• Sandoval C, Venkateswaran L, Billups C, . Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002;24:269–273.
   PubMed Web of Science ®Google Scholar
• van Grotel M, Lam KH, de Man R, . High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma 2006;47:1504–1510.
   PubMed Web of Science ®Google Scholar
• Shankar AG, Daw S, Hall G, . Treatment of children & adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma with a low intensity short duration chemotherapy regimen [CVP] - on behalf of the EuroNet-PHL Group. Blood 2006;108 (Suppl. 1): Abstract 2471.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol 2010;28:e8.
   PubMed Web of Science ®Google Scholar
• Ekstrand BC, Lucas JB, Horwitz SM, . Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285–4289.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Bartlett NL, Breslin S, . Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood 2007;110(Suppl. 1): Abstract 644.
   Google Scholar
• Schulz H, Rehwald U, Morschhauser F, . Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109–111.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, . An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010;116(Suppl. 1): Abstract 6.
   Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Skinnider B, Al Mansour M, . Incorporation of ABVD increases cure rates of patients with limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Blood 2010;116(Suppl. 1): Abstract 3887.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, . A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310–314.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Anderson JR, Freeman MB, . High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996;7:151–156.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293–2300.
   PubMed Web of Science ®Google Scholar
• Al-Mansour M, Connors JM, Gascoyne RD, . Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010;28:793–799.
   PubMed Web of Science ®Google Scholar
• Hancock JC, Wells A, Halling KC, . Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Ann Diagn Pathol 1999;3:23–34.
   PubMedGoogle Scholar
• Huang JZ, Weisenburger DD, Vose JM, . Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004;45:1551–1557.
   PubMed Web of Science ®Google Scholar
• Wickert RS, Weisenburger DD, Tierens A, . Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 1995;86:2312–2320.
   PubMed Web of Science ®Google Scholar
• Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:266–272.
   PubMedGoogle Scholar